Presentation is loading. Please wait.

Presentation is loading. Please wait.

THE PHARMACEUTICAL INDUSTRY OF PAKISTAN Presented By: Sara Shahab Lodhi8614 Ammara Ather8731 Sara Khan10156.

Similar presentations


Presentation on theme: "THE PHARMACEUTICAL INDUSTRY OF PAKISTAN Presented By: Sara Shahab Lodhi8614 Ammara Ather8731 Sara Khan10156."— Presentation transcript:

1 THE PHARMACEUTICAL INDUSTRY OF PAKISTAN Presented By: Sara Shahab Lodhi8614 Ammara Ather8731 Sara Khan10156

2 INDUSTRY OVERVIEW  Pakistan has a very vibrant and forward looking Pharma Industry.  Pakistan Pharmaceutical Industry meets around 70% of the country's demand of Finished Medicine.  The National Pharma industry has shown a progressive growth over the years, particularly over the last one decade.

3 INDUSTRY OVERVIEW (cont…)  The value of pharmaceuticals sold in 2007 exceeded US$1.4bn, which equates to per capita consumption of less than US$ 10 per year and value of medicines sold is expected to exceed US$2.3 B by 2012.  Pakistan is a developing pharmaceutical market, with a large population and economic progress.

4 INDUSTRY OVERVIEW (cont…)  The Pakistan Pharmaceutical Industry is a success story, providing high quality essential drugs at affordable prices to Millions.

5 PAKISTAN PHARMACEUTICAL MANUFACTURERS’ ASSOCIATION  Pakistan Pharmaceutical Manufacturers' Association came into existence on January 26, 1961.  The Government of Pakistan through the Ministry of Commerce registered PPMA as the only Representative body of the Pharmaceutical Industry in the Country.

6 PAKISTAN PHARMACEUTICAL MANUFACTURERS’ ASSOCIATION (cont…)  PMA has its head office located at KARACHI with two Regional offices, viz. Punjab & NWFP Regional Office at Lahore and Sindh & Balochistan Regional Office at Karachi.

7 IMPORTANCE OF PHARMA INDUSTRY  Produces medicines and life saving drugs  Contributes towards GDP (0.16%)  Generates employment (70,000 directly and 150,000 indirectly)  Supports Health facilities

8 KEY FACTS RanksPakistan 1 Glaxo Smith Kline 2 Abbott 3 Sanofi Aventis 4 Sami 5 Getz 6 Pfizer 7 Novertis 8 Roche 9 Searle 10 Remington

9 KEY FACTS (cont…)

10 PHARMACEUTICAL CAPITAL  The pharmaceutical industry exceeds $1.4bn which equates to per capita consumption of less than $10 per year.  Strong export potential: More than $100m foreign exchange earned annually for the country.  Pharmaceuticals: PKR152.97bn (US$1.79bn) in 2010 to PRK169.90bn (US$1.98bn) in 2011; +11.1% in local currency terms and +10.6% in US dollar terms.

11 PHARMACEUTICAL CAPITAL (cont…) Health care: PKR398.59bn (US$4.67bn) in 2010 to PKR454.63bn (US$5.31bn) in 2011; +14.1% in local currency terms and +13.5% in US dollar terms. Medical devices: PKR29.91bn (US$351mn) in 2010 to PKR34.87bn (US$407mn) in 2011; +16.6% in local currency terms and +16.1% in US dollar terms. (3) source: http://www.medpk.com/pharmceutical_overview.phphttp://www.medpk.com/pharmceutical_overview.php

12 HISTORICAL BACKGROUND  At the time of independence there were two small units which were unable to meet the local demand.  A decision was taken 1972 during the period of Bhutto to abolish the brand names.  There were only 3636 registered drugs in 1977. The number however rose to 6228 in 1981, and almost 9900 were reported in 1999.

13 HISTORICAL BACKGROUND (cont…)  In 1993, there were 256 national pharmaceutical units and 38 Multinational Companies. Pakistan pharmaceutical industry was valued at $900 million which grew @ 20% in 1996.  At the end of 1999 more than 75,000 medicines were being sold in the market. At the end of 1999, according to the Ministry of Health, there were 300 registered units producing medicines and other pharmaceuticals.

14 HISTORICAL BACKGROUND (cont…)  In 2006 there were over 400 licensed pharmaceutical companies in Pakistan, including 30 multinationals who had over 53 percent of market share.  Today, the industry has developed technology, production and an infrastructure of imports. It's a well regulated industry.

15 CURRENT SITUATION  Pharmaceutical industry of Pakistan is around US$ 2 billion with an annual growth rate of 12.9% per annum.  Out of total market of US$ 2 billion, 53.3% is captured by Multinationals and 46.7% is taken up by National companies.

16 CURRENT SITUATION (cont…)  High competition and price wars.  The top 50 firms enjoy more than 80% of the market share.

17 CURRENT SITUATION  Formulation  Basic manufacturing  Semi-basic manufacturing  Repacking

18 SOME KEY STATISTICS OF THE INDUSTRY

19 CHALLENGES TO THE PHARMACEUTICAL INDUSTRY  Market access is challenging and operational risks are high  Import of raw material which costs a lot of precious foreign exchange  Increasing cost of manpower and energy  Low R&D expenditure,  Political instability is another major factor  The deteriorating law and order situation, due to which most of companies have suffered in terms of sales

20 PRODUCTS OF SANOFI-AVENTIS

21 Products of Pfizer

22 PORTER’S FIVE FACTORS ANALYSIS

23 THE THREAT OF NEW ENTRANTS High Medium Low

24 THREAT OF SUBSTITUTE PRODUCTS High Medium Low

25 BARGAINING POWER OF SUPPLIERS High Medium Low

26 BARGAINING POWER OF BUYERS High Medium Low

27 RIVALRY AMONG EXISTING FIRMS PTPT PTPT ESES ESES High Medium Low

28 HEALTH SECTOR ISSUES

29 CONCLUSION  One of the most developed hi-tech sectors within the country's economy  Strong export potential  Drugs are available at low price to the consumers and the Ministry of Health is not considering the price increase due to the political influence  Per capita expenditure on drugs usage is also the lowest in the region (India, Bangladesh)  Counterfeit medicines are major problem  The drug inspection teams investigating the manufacture and sale of fake drugs have failed to perform their duty effectively

30 RECOMMENDATIONS  Prices to be increased in a balanced way  World class Laboratory should be established to conduct efficacy, quality, safety and bioavailability of products  Pharmacists to be available at medical stores to guide customers  Govt. must support the pharmaceutical industry by subsidizing this sector  The companies must allocate a fund for the promotion of R&D in Pakistan

31 RECOMMENDATIONS FOR COMPANIES  Collaboration with Indian companies  Pakistani exporters need to focus on African regions  Aggressive promotional campaign identifying Pakistan with quality products in the international market  Collaboration between the academic institutes and industry

32 GOVERNMENT SPECIFIC ACTIONS  Effective action against unethical marketing practices  Provide research infrastructure and labs to the domestic universities and academic institutions  Government incentives on R&D, encouraging companies to set up their own R&D units and manufacturing units in tax free zones  Government should collaborate with UN and the WHO programs to support the industry  Government should put a ban on import of generics being produced locally

33 GOVERNMENT SPECIFIC ACTIONS (cont…)  Government should suspend its requirement of separating the drug production lines, because it will be very difficult for smaller companies to meet this requirement  Government should also provide loans to the local companies to establish separate drug production lines  Since this can be the only way for the smaller companies to meet this requirement  Government can attract investors for investment in this sector by announcing incentives for them  In this way, the raw material will be available to the manufacturers at a cheaper rate

34 GOVERNMENT SPECIFIC ACTIONS (cont…)  The Govt. actions can be fruitful only when the pharmaceutical industry as a whole gives a positive response  The pharmaceutical sector itself must show a corporate responsible behavior in receiving and responding to the incentives

35


Download ppt "THE PHARMACEUTICAL INDUSTRY OF PAKISTAN Presented By: Sara Shahab Lodhi8614 Ammara Ather8731 Sara Khan10156."

Similar presentations


Ads by Google